Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
Convalescent plasma has been extensively tested during the COVID-19 pandemic as a transfusion product. Similarly, monoclonal antibodies have been largely administered either intravenously or intramuscularly. Nevertheless, when used against a respiratory pathogen, respiratory delivery is preferable t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2260040 |
| _version_ | 1797633732295786496 |
|---|---|
| author | Daniele Focosi Fabrizio Maggi |
| author_facet | Daniele Focosi Fabrizio Maggi |
| author_sort | Daniele Focosi |
| collection | DOAJ |
| description | Convalescent plasma has been extensively tested during the COVID-19 pandemic as a transfusion product. Similarly, monoclonal antibodies have been largely administered either intravenously or intramuscularly. Nevertheless, when used against a respiratory pathogen, respiratory delivery is preferable to maximize the amount of antibody that reaches the entry door in order to prevent sustained viral multiplication. In this narrative review, we review the different types of inhalation device and summarize evidence from animal models and early clinical trials supporting the respiratory delivery (for either prophylactic or therapeutic purposes) of convalescent plasma or monoclonal antibodies (either full antibodies, single-chain variable fragments, or camelid-derived monoclonal heavy-chain only antibodies). Preliminary evidences from animal models suggest similar safety and noninferior efficacy, but efficacy evaluation from clinical trials is still limited. |
| first_indexed | 2024-03-11T11:57:59Z |
| format | Article |
| id | doaj.art-a106c5a6275c44078dc6cafed591f20c |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:57:59Z |
| publishDate | 2023-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-a106c5a6275c44078dc6cafed591f20c2023-11-08T11:55:20ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-08-0119210.1080/21645515.2023.22600402260040Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapyDaniele Focosi0Fabrizio Maggi1Pisa University HospitalNational Institute for Infectious Diseases “Lazzaro Spallanzani IRCCS”Convalescent plasma has been extensively tested during the COVID-19 pandemic as a transfusion product. Similarly, monoclonal antibodies have been largely administered either intravenously or intramuscularly. Nevertheless, when used against a respiratory pathogen, respiratory delivery is preferable to maximize the amount of antibody that reaches the entry door in order to prevent sustained viral multiplication. In this narrative review, we review the different types of inhalation device and summarize evidence from animal models and early clinical trials supporting the respiratory delivery (for either prophylactic or therapeutic purposes) of convalescent plasma or monoclonal antibodies (either full antibodies, single-chain variable fragments, or camelid-derived monoclonal heavy-chain only antibodies). Preliminary evidences from animal models suggest similar safety and noninferior efficacy, but efficacy evaluation from clinical trials is still limited.http://dx.doi.org/10.1080/21645515.2023.2260040convalescent plasmamonoclonal antibodiesnasal immunotherapiespassive immunotherapiessars-cov-2covid-19spikeneutralizing antibodies |
| spellingShingle | Daniele Focosi Fabrizio Maggi Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy Human Vaccines & Immunotherapeutics convalescent plasma monoclonal antibodies nasal immunotherapies passive immunotherapies sars-cov-2 covid-19 spike neutralizing antibodies |
| title | Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy |
| title_full | Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy |
| title_fullStr | Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy |
| title_full_unstemmed | Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy |
| title_short | Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy |
| title_sort | respiratory delivery of passive immunotherapies for sars cov 2 prophylaxis and therapy |
| topic | convalescent plasma monoclonal antibodies nasal immunotherapies passive immunotherapies sars-cov-2 covid-19 spike neutralizing antibodies |
| url | http://dx.doi.org/10.1080/21645515.2023.2260040 |
| work_keys_str_mv | AT danielefocosi respiratorydeliveryofpassiveimmunotherapiesforsarscov2prophylaxisandtherapy AT fabriziomaggi respiratorydeliveryofpassiveimmunotherapiesforsarscov2prophylaxisandtherapy |